| TNFRSF25 - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3
Abbreviation: TNFRSF25, DR3
Alternative Names: Death Receptor 3, APO-3, LARD, TRAMP, WSL-1, TR3
Type: Tumor necrosis factor receptor superfamily member / death receptor / immune signaling receptor
Function: DR3 is a type I transmembrane receptor containing an intracellular death domain. Its principal ligand is TL1A/TNFSF15. DR3 signaling can recruit adaptor proteins including TRADD and activate caspase-dependent apoptosis, necroptosis, NF-κB, JNK, and immune-cell activation pathways.
Cancer: ↕ Context-dependent. DR3 activation can induce apoptosis or necroptosis in cancer cells and can enhance antitumor immune responses. However, DR3 can also activate NF-κB-dependent survival or inflammatory signaling, and certain splice variants have been associated with invasion and metastasis in selected cancers.
Favorable Direction in Cancer: Context-dependent. ↑ DR3 death-signaling can be favorable where it promotes apoptosis or necroptosis, whereas ↓ DR3 signaling may be favorable in tumors where DR3 promotes survival, inflammation, invasion, or metastasis.
Interpretation Note: Do not confuse DR3/TNFRSF25 with DcR3/TNFRSF6B. DcR3 is a soluble decoy receptor and is a distinct target.
|